Is AnaptysBio Inc (ANAB) overvalued? · rev $91.3M
AnaptysBio Inc (ANAB) is a biotechnology company listed on NASDAQ.
This page asks whether AnaptysBio Inc (ANAB) looks expensive on cached numbers — not a short thesis.
Latest reported ANAB revenue for 2024-12-31 was $91.3M. Net income was -$145.2M. Revenue was up 432.0% from 2023-12-31 to 2024-12-31. ANAB currently screens at market cap $1.62B.
ANAB currently screens at market cap $1.62B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ANAB 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ANAB stock page for the full model, not this heading.
Not investment advice.